Orphazyme A/S
Company announcement                                                                                                                  
No. 07/2019                                                                                                                                        
Company Registration No. 32266355

                                                                                                                                                                                            

Copenhagen, Denmark, March 5, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by closely associated persons to persons discharging managerial responsibilities in Orphazyme:

1 Details of the Reporting Person / Closely Associated Person
a) Name
GFD Investments LLC
2 Reason for the notification
a) Position/status
Closely associated person to Georges Gemayel, Chairman of the Board of Directors
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 48.80	525
DKK 48.80	19
DKK 48.80	643
DKK 48.80	180
DKK 49.00	40
DKK 49.00	874
DKK 48.05	289
DKK 47.00	1,989
DKK 50.00	520
DKK 50.00	1,000
DKK 50.00	225
DKK 50.00	70
DKK 49.00	427
DKK 49.50	126
DKK 49.90	700
DKK 50.00	363
DKK 49.00	895
DKK 49.90	212
DKK 49.90	501
DKK 49.85	2

d) Aggregated information

 

• Aggregated volume
• Price

 

Aggregated volume: 9,600
Price: DKK 48.8946
e) Date of the transaction
2019-03-04 – between 10:00 and 13:00 UTC-time
f) Place of the transaction
Nasdaq Copenhagen A/S - XCSE

 

For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55

 

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com. 

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

Reporting of transactions in Orphazymes shares